Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Schwetz, V; Schnedl, C; Urbanic-Purkart, T; Trummer, C; Dimai, HP; Fahrleitner-Pammer, A; Putz-Bankuti, C; Christopher, KB; Obermayer-Pietsch, B; Pieber, TR; Dobnig, H; Amrein, K.
Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study.
Osteoporos Int. 2017; 28(12):3347-3354 Doi: 10.1007/s00198-017-4190-1 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Amrein Karin
Theiler-Schwetz Verena
Co-Autor*innen der Med Uni Graz
Dimai Hans Peter
Dobnig Harald
Fahrleitner-Pammer Astrid
Obermayer-Pietsch Barbara
Pieber Thomas
Putz-Bankuti Csilla
Schnedl Christian
Trummer Christian
Urbanic Purkart Tadeja

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

In this post hoc analysis of the VITdAL-ICU study, an RCT in critically ill adults with 25-hydroxyvitamin D levels ≤20 ng/ml, vitamin D3 did not have a significant effect on β-Crosslaps and osteocalcin. Observational studies have shown accelerated bone loss in ICU survivors. A reversible contributor is vitamin D deficiency. In a post hoc analysis of the VITdAL-ICU study, we evaluated the effect of high-dose vitamin D3 on the bone turnover markers (BTM) β-Crosslaps (CTX) and osteocalcin (OC). The VITdAL-ICU study was a randomized, double-blind, placebo-controlled trial in critically ill adults with 25-hydroxyvitamin D levels ≤20 ng/ml who received placebo or high-dose vitamin D3 (a loading dose of 540,000 IU and starting 1 month after the loading dose five monthly maintenance doses of 90,000 IU). In this analysis on 289 survivors (209 telephone, 80 personal follow-up visits), BTM were analyzed on days 0, 3, 7, 28, and 180; self-reported falls and fractures were assessed. Bone mineral density (BMD) was measured after 6 months. At baseline, CTX was elevated; OC was low in both groups-after 6 months, both had returned to normal. There were no differences between groups concerning BTM, BMD, falls, or fractures. In linear mixed effects models, CTX and OC showed a significant change over time (p < 0.001, respectively), but there was no difference between the vitamin D and placebo group (p = 0.688 and p = 0.972, respectively). Vitamin D supplementation did not have a significant effect on BTM. Further studies should assess the effectiveness of vitamin D on musculoskeletal outcomes in ICU survivors.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Bone Density - drug effects
Bone Density Conservation Agents - pharmacology
Bone Density Conservation Agents - therapeutic use
Bone Remodeling - drug effects
Bone Remodeling - physiology
Cholecalciferol - pharmacology
Cholecalciferol - therapeutic use
Collagen - blood
Critical Illness - therapy
Double-Blind Method -
Female -
Follow-Up Studies -
Humans -
Intensive Care Units -
Male -
Middle Aged -
Osteocalcin - blood
Peptide Fragments - blood
Vitamin D - analogs & derivatives
Vitamin D - blood
Vitamin D Deficiency - blood
Vitamin D Deficiency - drug therapy
Vitamin D Deficiency - physiopathology

Find related publications in this database (Keywords)
Bone loss
Bone mineral density
Bone turnover markers
Critical illness
Long-term outcomes
Vitamin D3
© Med Uni Graz Impressum